{"slug":"selank","verification":{"valid":true,"entries":40,"head":"206d58e1fc32b21cb5d1166cae73b49e9ce3144dc6940aaf1985e2e9f00a2b3f"},"energy":{"passes":40,"tokens_in":3222,"tokens_out":286,"tokens_total":3508,"cost_usd":0,"models":{"grok/grok-4.3":1,"grok-4.3":22,"repair":2,"system/audit-repair":11,"kimi/moonshot-v1-8k":1,"fill-slots":2,"owner":1},"head":"206d58e1fc32b21cb5d1166cae73b49e9ce3144dc6940aaf1985e2e9f00a2b3f"},"provenance":[{"ts":"2026-06-29T08:32:35.557Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):\nBPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).\nTB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.\nARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.\nSemax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.\nSelank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).\nPT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).\nDSIP — Delta Sleep Inducing Peptide; natural deep sleep without Ambien-class hangover.\nKPV — Gut-specific anti-inflammatory; calms gut lining without systemic immune suppression.\nGHK-Cu — Tissue remodeling; builds collagen scaffolding. Production drops 60-80% with age.\nThymosin Alpha-1 — Immune modulation; supports immune function without suppressing it.\n\nWrite a data-first, evidence-graded article: Selank: Non-Sedating Anxiolytic\n\nGeneral evidence-graded intro for Selank: Non-Sedating Anxiolytic. Data-first peptide definition article.\n\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate rat studies from human trials from user reports. No medical claims or treatment promises. Use repair-vs-suppression framing where relevant. register: source_ledger.","response":"{\n  \"slug\": \"selank-non-sedating-anxiolytic\",\n  \"title\": \"Selank: Non-Sedating Anxiolytic\",\n  \"body\": \"## Overview\\nSelank is a synthetic heptapeptide derived from tuftsin with reported anxiolytic properties.\\n\\n## Human Data\\nA 2008 randomized study compared intranasal Selank to medazepam in 62 patients with generalized anxiety disorder and neurasthenia.\\n\\n## Preclinical Data\\nRat studies show alterations in gene expression related to neurotransmission.\\n\\n## Mechanism\\nProposed allosteric effects on GABA_A receptors without direct agonism.\",\n  \"register\": \"source_ledger\",\n  \"claims\": [\n    {\n      \"id\": \"c1\",\n      \"text\": \"In a 2008 randomized study of 62 patients with GAD and neurasthenia, Selank showed anxiolytic efficacy comparable to medazepam on psychometric scales without reported sedation, cognitive impairment, tolerance or withdrawal.\",\n      \"section\": \"Human Data\",\n      \"tier\": \"human\",\n      \"source_ids\": [\"s1\"],\n      \"source_status\": \"sourced\",\n      \"why_material\": \"Primary human trial evidence separating Selank from benzodiazepine side-effect profile.\"\n    },\n    {\n      \"id\": \"c2\",\n      \"text\": \"Selank administration in rats alters expression of 45 neurotransmission-related genes at 1 hour and 22 genes at 3 hours, with positive correlation to GABA effects.\",\n      \"section\": \"Preclinical Data\",\n      \"tier\": \"preclinical\",\n      \"source_ids\": [\"s2\"],\n      \"source_status\": \"sourced\",\n      \"why_material\": \"Direct evidence from controlled animal gene-expression experiments.\"\n    },\n    {\n      \"id\": \"c3\",\n      \"text\": \"Clinical observations indicate Selank produces effects similar to low-dose benzodiazepines via potential allosteric modulation of GABA_A receptors but without amnesia, dependence or sedation.\",\n      \"section\": \"Mechanism\",\n      \"tier\": \"mechanistic\",\n      \"source_ids\": [\"s1\", \"s2\"],\n      \"source_status\": \"sourced\",\n      \"why_material\": \"Links observed human outcomes to proposed receptor-level action distinct from classical b","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"615fe50094660612340033d9365d4bd4a49779882e4671f9d2c7aa16d26038fc"},{"ts":"2026-06-29T09:43:07.014Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"615fe50094660612340033d9365d4bd4a49779882e4671f9d2c7aa16d26038fc","hash":"5ebbd9cc4bc5c9ab2bed9e2c428113233e3c29d357a6bde54a0fbc3a8481d3e1"},{"ts":"2026-06-29T09:43:20.743Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5ebbd9cc4bc5c9ab2bed9e2c428113233e3c29d357a6bde54a0fbc3a8481d3e1","hash":"33954264ea5ad441efcf1e6542e7027efeed0bdbbde8f4dcf2b43cac27e236a9"},{"ts":"2026-06-29T09:43:38.897Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"10 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"33954264ea5ad441efcf1e6542e7027efeed0bdbbde8f4dcf2b43cac27e236a9","hash":"2d1a3d70e34dc5ee2c7f3345d87e4be57b103dd794efc585da3e1c81287e6ee7"},{"ts":"2026-06-29T09:43:57.316Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"2d1a3d70e34dc5ee2c7f3345d87e4be57b103dd794efc585da3e1c81287e6ee7","hash":"8eac03e1cfca1afefbc8d9bfef1dcbb0d39d03ae56250613a6fb26376c94721c"},{"ts":"2026-06-29T09:45:12.074Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8eac03e1cfca1afefbc8d9bfef1dcbb0d39d03ae56250613a6fb26376c94721c","hash":"04292873e1a184a0638a9e65088936a02f3b82cae94ca3cdeffda080be2cd38e"},{"ts":"2026-06-29T09:45:32.737Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"04292873e1a184a0638a9e65088936a02f3b82cae94ca3cdeffda080be2cd38e","hash":"f9d70763a451944d0afcad6df95c8573b53c56e5c4184d27a3b895c692e9e99b"},{"ts":"2026-06-29T09:46:00.316Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f9d70763a451944d0afcad6df95c8573b53c56e5c4184d27a3b895c692e9e99b","hash":"c40f1e94b528c089a4184132948558043f2ea97f60e9200aa056bdb075e85585"},{"ts":"2026-06-29T09:46:17.979Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c40f1e94b528c089a4184132948558043f2ea97f60e9200aa056bdb075e85585","hash":"fa091462e00c40016c76300d7e2e09364f877e73fcdb69a4d32655fcd37f3de9"},{"ts":"2026-06-29T09:47:08.082Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"fa091462e00c40016c76300d7e2e09364f877e73fcdb69a4d32655fcd37f3de9","hash":"2eeae96297f590b117734b14a06fed87541eb1e187e234d3b5686113c431be71"},{"ts":"2026-06-29T09:47:25.422Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"7 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"2eeae96297f590b117734b14a06fed87541eb1e187e234d3b5686113c431be71","hash":"5b0e38014ad2c35c266fe9c151050cf5ed7695fd684d055737426ee0def10700"},{"ts":"2026-06-29T09:47:40.158Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5b0e38014ad2c35c266fe9c151050cf5ed7695fd684d055737426ee0def10700","hash":"daa4932b80c3e7576d16bd6d0660b11b9da9d1d731db4a8657547731eb2112ec"},{"ts":"2026-06-29T09:48:04.106Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"daa4932b80c3e7576d16bd6d0660b11b9da9d1d731db4a8657547731eb2112ec","hash":"810eb94e143ad162529d8114102a21126389475618244e7c3d6d43dd80c193c6"},{"ts":"2026-06-29T12:29:45.660Z","model":"repair","action":"repair","prompt":"","input":"selank","response":"{\"materialized\":65,\"before\":[\"3 claims missing posted_by\",\"65 orphan sources (no claim link)\",\"missing constitution slots: what_it_is, who_claims_what, what_is_known, what_is_unknown, limitations, disclaimer\"],\"after\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"810eb94e143ad162529d8114102a21126389475618244e7c3d6d43dd80c193c6","hash":"127784d4f502306a8fb34f7fed0e4c7e14a513f8d08ea1faa5995d73cc2730bf"},{"ts":"2026-06-29T12:45:15.479Z","model":"system/audit-repair","action":"repair","prompt":"","input":"selank","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"],\"after\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"127784d4f502306a8fb34f7fed0e4c7e14a513f8d08ea1faa5995d73cc2730bf","hash":"26660f41c65024f4ff540f7e7d1b77d2734118fda71c3e79735cc9ece8dfb93f"},{"ts":"2026-06-29T12:45:16.100Z","model":"system/audit-repair","action":"claim","prompt":"","input":"selank c69","response":"Selank: Non-Sedating Anxiolytic is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"26660f41c65024f4ff540f7e7d1b77d2734118fda71c3e79735cc9ece8dfb93f","hash":"63203667f4fefca7dd5bc56bea1bb9401e2235669eec6a117798217f6a2e4f68"},{"ts":"2026-06-29T12:45:16.317Z","model":"system/audit-repair","action":"claim","prompt":"","input":"selank c70","response":"Per this ledger on Selank: Non-Sedating Anxiolytic: 31 scientific and 35 anecdotal sources are catalogued; 17 preclinical claim(s) summarize animal/cell literature in-catalogue.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"63203667f4fefca7dd5bc56bea1bb9401e2235669eec6a117798217f6a2e4f68","hash":"5549b9b0e1baa86c3788462eb273dd75c24fc1e8679c337b78dee0d60ba55987"},{"ts":"2026-06-29T12:45:16.573Z","model":"system/audit-repair","action":"claim","prompt":"","input":"selank c71","response":"Not established in this ledger: large randomized human trials for common marketed uses; long-term human safety beyond small pilots; condition-specific efficacy where only anecdotal or preclinical sources exist (explicit gaps remain in question graph).","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5549b9b0e1baa86c3788462eb273dd75c24fc1e8679c337b78dee0d60ba55987","hash":"5d58a1900c8d06020f4fc3f3e412351201a7f29c01ecc361434aaff2a4580b24"},{"ts":"2026-06-29T12:45:16.642Z","model":"system/audit-repair","action":"claim","prompt":"","input":"selank c72","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5d58a1900c8d06020f4fc3f3e412351201a7f29c01ecc361434aaff2a4580b24","hash":"7a4859fb5afb4fb0d20b32a5bc007e732499634b7b5038de1a4f9a1cb8524ea0"},{"ts":"2026-06-29T12:45:16.915Z","model":"system/audit-repair","action":"claim","prompt":"","input":"selank c73","response":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7a4859fb5afb4fb0d20b32a5bc007e732499634b7b5038de1a4f9a1cb8524ea0","hash":"6dfd9e989d67306680d5d42f41f73c7291db71815d7f7fcffdb4569cf279f662"},{"ts":"2026-06-29T12:45:17.836Z","model":"system/audit-repair","action":"repair","prompt":"","input":"selank","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6dfd9e989d67306680d5d42f41f73c7291db71815d7f7fcffdb4569cf279f662","hash":"32cce2d1848769099b33cd15db3d9c9e71aa09cf40c448a4b513243484370238"},{"ts":"2026-06-29T12:45:55.352Z","model":"system/audit-repair","action":"repair","prompt":"","input":"selank","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"32cce2d1848769099b33cd15db3d9c9e71aa09cf40c448a4b513243484370238","hash":"3f72cd1f223473ef97301897fbdd1c728ac066af2e9e9730df9aff995a168b5e"},{"ts":"2026-06-29T12:45:56.526Z","model":"system/audit-repair","action":"repair","prompt":"","input":"selank","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"3f72cd1f223473ef97301897fbdd1c728ac066af2e9e9730df9aff995a168b5e","hash":"0668ba07de83e513da983ed68344b7dc9c9e3c43ed93063831c28667e30b0cee"},{"ts":"2026-06-29T13:25:50.825Z","model":"system/audit-repair","action":"repair","prompt":"","input":"selank","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0668ba07de83e513da983ed68344b7dc9c9e3c43ed93063831c28667e30b0cee","hash":"7f3f615e1850b4145dc29f726e6b34c38ce3b7f29a5792981eb248e05a71efc2"},{"ts":"2026-06-29T13:25:52.034Z","model":"system/audit-repair","action":"repair","prompt":"","input":"selank","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7f3f615e1850b4145dc29f726e6b34c38ce3b7f29a5792981eb248e05a71efc2","hash":"5952fe889245f1d5b20f71d8353096c18d14f7275975d521977db2dcb8dd4685"},{"ts":"2026-06-29T14:01:46.327Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"selank","response":"I am adding claims to address explicit gaps in the ledger, specifically identifying what is unknown and naming who claims what from anecdotes where missing, as instructed.","tokens_in":3222,"tokens_out":286,"cost":0,"prev":"5952fe889245f1d5b20f71d8353096c18d14f7275975d521977db2dcb8dd4685","hash":"8c5f301307ec498f83d2672a38afd40f381e2799b2cbe24dff7ccc7341ed4b46"},{"ts":"2026-06-29T15:28:36.456Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8c5f301307ec498f83d2672a38afd40f381e2799b2cbe24dff7ccc7341ed4b46","hash":"40514111bbb89af2c2e5ea3ee027882658bff74517ff017c4e612e06c63e65cc"},{"ts":"2026-06-29T15:29:05.866Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"40514111bbb89af2c2e5ea3ee027882658bff74517ff017c4e612e06c63e65cc","hash":"d7ee9f4249c502f696bfc94c98537e5ecfa5e514a7329b3117793f3f5655a880"},{"ts":"2026-06-29T15:29:39.405Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d7ee9f4249c502f696bfc94c98537e5ecfa5e514a7329b3117793f3f5655a880","hash":"a137a6392f6c96163d1f5eaa1144e98b1243e3a1048077fe1d36909ce560cace"},{"ts":"2026-06-29T15:30:21.228Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a137a6392f6c96163d1f5eaa1144e98b1243e3a1048077fe1d36909ce560cace","hash":"5f13c04e971c002d28514d7ee2a298eaacd777da5fdb6ad5d968dc6717accc02"},{"ts":"2026-06-29T15:30:53.242Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5f13c04e971c002d28514d7ee2a298eaacd777da5fdb6ad5d968dc6717accc02","hash":"d63a248fa7378a475a974bf86c755d0602593bf03a7d54bf28efcef718ba8b19"},{"ts":"2026-06-29T17:31:33.757Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d63a248fa7378a475a974bf86c755d0602593bf03a7d54bf28efcef718ba8b19","hash":"07fb1945b87e48455e1374d88675d05df86a88ff969fbd3b94cf1a819cdfcaff"},{"ts":"2026-06-29T17:31:58.704Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"07fb1945b87e48455e1374d88675d05df86a88ff969fbd3b94cf1a819cdfcaff","hash":"20812c88b85b69a66184ca1f799bd3e6a4b1c9bbc9c011eada606a605e21bbe3"},{"ts":"2026-06-29T17:32:32.177Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"20812c88b85b69a66184ca1f799bd3e6a4b1c9bbc9c011eada606a605e21bbe3","hash":"cb5c57b8d9749c71c46bee8d5aab166d75a1fe3172bb9b607c1c336bebe3d0e0"},{"ts":"2026-06-29T17:33:23.924Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"cb5c57b8d9749c71c46bee8d5aab166d75a1fe3172bb9b607c1c336bebe3d0e0","hash":"5f3a5ded9cb296d5231c2cbbfc87d7a70062b4158a263a64acc35fa35f43230f"},{"ts":"2026-06-29T17:33:49.941Z","model":"grok-4.3","action":"sources","prompt":"","input":"selank","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5f3a5ded9cb296d5231c2cbbfc87d7a70062b4158a263a64acc35fa35f43230f","hash":"1733136cf449ea76307d700141a70f4bebcb6ca7d6a8d5a557c1daf5ca5049aa"},{"ts":"2026-06-29T19:25:02.689Z","model":"repair","action":"repair","prompt":"","input":"selank","response":"{\"materialized\":0,\"before\":[],\"after\":[],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":0,\"adjacent\":12}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1733136cf449ea76307d700141a70f4bebcb6ca7d6a8d5a557c1daf5ca5049aa","hash":"e3018f3c2a6b17bc5e802b64074da3f2073f637d6b93a14f386c90e55d81c7a8"},{"ts":"2026-06-29T20:39:05.873Z","model":"fill-slots","action":"claim","prompt":"","input":"selank c101","response":"Selank: Non-Sedating Anxiolytic is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e3018f3c2a6b17bc5e802b64074da3f2073f637d6b93a14f386c90e55d81c7a8","hash":"060f2dadab51a02f1d28a6b9618355dc2f6706dff82bb0d97305abc048fd7267"},{"ts":"2026-06-29T20:39:07.527Z","model":"fill-slots","action":"claim","prompt":"","input":"selank c102","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"060f2dadab51a02f1d28a6b9618355dc2f6706dff82bb0d97305abc048fd7267","hash":"12c6083b6a579c8651a250fed7b980b8acf6718143052c5058dab9ef9c3ce4bf"},{"ts":"2026-07-17T02:41:34.131Z","model":"owner","action":"voxel_divide","prompt":"","input":"selank","response":"8 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"12c6083b6a579c8651a250fed7b980b8acf6718143052c5058dab9ef9c3ce4bf","hash":"206d58e1fc32b21cb5d1166cae73b49e9ce3144dc6940aaf1985e2e9f00a2b3f"}]}